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NOTE
Drug Liability -Survey, Study, and Prognosis
INTRODUCTION
In the last decade, few areas of the law have expanded as rapidly as
that of drug liability Perhaps Gottsdanker v Cutter Laboratores1 pre-
cipitated more interest and litigation in this area than any other single
factor. That decision was timely for many reasons. Improvements in
communication, commercialization of medicine, public interest in medical
problems, perfection of testing techniques, and new cures for widely
feared illnesses have all led to an informed and demanding public. The
public's expectations as to the quality of new drugs has been elevated, as
well as the legal concepts to meet those expectations. This Note will deal
with these changing expectations as reflected in the law of drug liability.
Consideration will be given primarily to a "horizontal" presentation of
the drug liability problem; a "vertical" approach or analysis of the many
legal issues involved will be treated only secondarily.
This survey of drug liability will include a discussion of such drugs
as thalidomide, Parnate, Mer/29, and the Sabin Oral Vaccine. More
specifically, this discussion will examine what impact these new and "ex-
perimental" wonder drugs have had and will have on drug laws, both
civil and criminal; how the concepts of warranty and negligence have
changed; the technical problems facing the parties, %.e., lawyers, drug
manufacturers, legislators, doctors and pharmacists; and what effect com-
petition has had in increasing costs and public demand.
CAUSATION
Proving the causal connection between use of a defendant's drug and
a plaintiff's injury is one of the most difficult problems facing parties in
new drug litigation. Obviously, causation is easier to establish when
there is a large number of injuries available to examine and compare.
The new drugs, however, present unique problems in that only some users
experience unusual and unintended side effects. Consequently, expert
medical researchers must make comparisons and devise and adapt tests to
determine whether these injuries are a result of using a particular drug.
These studies are directed toward improving drugs and defining the risks
involved in their use. As a result, a drug is either improved, dropped,
or its use is knowledgeably controlled.
1. 182 Cal. App. 2d 602, 6 Cal. Rep. 320 (1960)
Drug Liability
For those injured by a drug, there may be recovery against the drug
manufacturer, doctors, handlers, and promoters. In determining this
liability, the attorney's problems with causation parallel those of the med-
ical researcher. Understanding the body chemistry involved with anti-
depressants, vaccines, or contraceptive pills requires more technical know-
how than that required for "simpler" injuries such as sprains, broken
bones, and bullet wounds. Thus, an attorney's medical acumen with re-
spect to drug litigation must approach, and in some instances even sur-
pass, that of the medical researchers.
The history of drug liability is replete with litigation involving the
negligence of druggists2 and manufacturers.3  There is a rather well de-
fined range of defects in drugs which has given rise to legally redressable
injury. Technically, drugs are susceptible to substitution of ingredients,4
impurities,5 poisons,0 harmful quanuties, or improper labelling.8  But
the new drugs present somewhat different types of defects. Very often
the ultimate problem is in knowing too little about the drug before it is
released. This stems from the inadequacy of testing procedures or,
simply, the imapossibility of devising procedures elaborate enough to de-
tect minute risks. In some instances drug companies de-emphasize or
overlook possible risks. In addition, some drugs are of such a nature that
they cannot be made as safe as originally desired. However, the benefits
may still outweigh the risks so as to justify the drug's release. The new
drugs may not be impure in the sense that they contain poison, but in
many instances, the injuries resulting from their use may be as serious as
though they did. New and experimental drugs generally work in strange
and often unknown ways in producing injury as well as cure. It is neces-
sary at this point to examine separately a representative group of these
drugs.
Salk Vaccine
The type of injuries caused by the Salk vaccine are now history; yet,
some discussion is required here with respect to the problem of causation.
The Salk vaccine is a preparation of "killed" (inactivated) polio viruses
which, when introduced into the body, stimulate development of specific
2. Annot., 79 A.L.R.2d 301 (1961); 18 OHIo JuR. 2d Drugs & Druggists §§ 25-31, at 472
(1958).
3. 2 FRmMER & FRIDMAN, PRODUCTS lIABI'rY § 33.01 (1961).
4. McGahey v. Albritton, 214 Ala. 279, 107 So. 751 (1926),; see also Hruska v. Parke,
Davis & Co., 6 F.2d 536 (8th Cir. 1925).
5. Abbott Lab. v. Lapp, 78 F.2d 170 (7th Cir. 1935).
6. David v. McKesson & Robbins Co., 253 App. Div. 728, 300 N.Y. Supp. 635 (1937),
aff'd, 278 N.Y. 622, 16 N.E.2d 127 ,(1938).
7. Blood Balm Co. v. Cooper, 83 Ga. 457, 10 S.E. 118 (1889).
8. Thomas v. Winchester, 6 N.Y. 397 (1852).
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antibodies which ward off future attacks by live polio viruses.' The
Cutter0 case, for example, involved the development of paralysis in chil-
dren Immunized with this killed vaccine. Other cases revealed paralysis
localized around the sites of the injection which, of course, simplified the
proof of causation. In such cases, it was discovered that some live polio
virus particles were, by clumping together,i" escaping the treatment with
formalin which was designed to kill them. The Cutter Company had fol-
lowed all government manufacturing procedures 2 and argued, therefore,
that this would obviate the charge that reasonable care was not observed.
However, negligence did not become a factor in granting of recovery,
since the suit was also based on a breach of warranty."3 Although it is
not necessary in a warranty action to show how the vaccine became con-
tammated, it is important in this discussion to note the real reason for
this injury in that it foreshadows a new aspect of drug causation analysis
- inadequate manufacturing and testing procedures.
Thalidomude
The story behind the distribution and use of thalidomide in the United
States typifies the abuses which lead to thousands of injuries and hundreds
of law suits. At first it was not known what effect thalidomide had
on the human body Because of its chemical structure it was tested
as a barbiturate, but was found to have absolutely no such effect on
animals. When tried as an anti-convulsant for epileptics, it was found
to have some sedative qualities and was thereafter marketed as a sleeping
pill and tranquilizer. In Germany, it was manufactured "by the ton" and
sold without prescription. 4 While in use, it produced few of the com-
mon side effects normally associated with the use of tranquilizers, such
as drowsiness or habit forming dependency. Although thalidomide was
widely used in Europe, it was used only on an experimental basis in the
United States as a result of wise caution exercised by one member of the
Food and Drug Administration (FDA) In this country, the drug was
given only to "selected" researchers for "limited" use."5
Tracng the Cause of Injury.-Slowly, the appearance of thousands
of deformed babies began to stun the public. The problem was a hidden
9. WILSON, MARGIN OF SAFETY 75-76 (1963)
10. Gottsdanker v. Cutter Labs., 182 Cal. App. 2d 602, 6 Cal. Rep. 320 (1960).
11. Id. at 610, 6 Cal. Rep. at 325.
12. Spencer, Where Are We Now on Polio?, Saturday Evening Post, Sept. 10, 1955, p. 19.
13. Negligence is not a factor in breach of warranty. Pabon v. Hackensack Auto Sales Inc.,
63 NJ. Super. 476, 164 A.2d 773 (1960) In the Cutter case neither Dr. Salk nor the
Government were considered liable for the wrong manufacturing directions.
14. Taussig, A Study of the German Outbreak of Phocomelia, 180 A.M.A.J. 1106-14 (1962).
15. Hearings on Interagency Coordination in Drug Research and Regulation Before the Sen-
ate Subcommittee on Reorganizattons of the Committee on Government Operations, 87th Cong.,
2d Sess., pt. 1, at 264-65 (1962).
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danger in the use of this drug by pregnant women which led to the birth
of babies with various deformities, the most common of which was pho-
comelia."6
A Senate subcommittee has mvestAgated the thalidomide story and
reported as follows: drug salesmen were directed to department chiefs
and senior members of medical and surgical staffs; their main purpose
was to establish local studies the results of wich would "spread the word"
among other staff members; detailed reporting was not required because
the FDA was sure to approve it very shortly; "basic clinical research had
been conducted" and the toxic safety well established."
Since the FDA required qualified investigators in experimental field
trials, the salesmen were told to be sure to obtain the doctors' signature
on the "statement of proposed investigation." Today, this requirement
of qualified investigators.is spelled out in the controversial section 505 (i)
of the 1962 amendments to the Federal Food, Drug and Cosmetics Act."
Within one week after the sales meeting described in the hearings,
the salesmen had helped to institute 162 studies, covering 6,648 patients.
Within a month there were 762 studies covering 29,413 patients. 9
16. Ibid. "Seal limbs" is the common term for phocomelia.
17. Hearings on Interagency Coordination in Drug Research and Regulation Before the Sen-
ate Subcommittee on Reorganization and International Organizations of the Committee on
Government Operations, 87th Cong., 2d Sess., pt. 1, at 262 (1962).
18. Federal Food, Drug and Cosmetic Act § 505(i), 76 Stat. 781 (1963), 21 U.S.C.
355 (i) (Supp. V, 1964).
This section has generated much discussion since its enactment in 1962. It exempts in.
vestigational drugs from certain other formal requirements. There are two points of inter-
est. One concerns the requirement that "experts qualified by scientific training and experi-
ence" be chosen to investigate new drugs. There are no other provisions defining the requisite
qualificatons of experts. The only requirement appears to be a statement signed by the
expert as to the limitations on the use of the drug. The second problem arises out of the
following section wbich appears to be self-neutralizing in effect:
IThe sponsor of the investigation [must also require the investigators to notify
the patients that they are being given drugs in an investigational program, obtain
their consent,) except [in cases where the investigator) deems it not feasible
or contrary to the best interests of [the patient to be so informed.) (Emphasis
added.)
This section is the subject of much concern because of the wide publicity given the in-
juries from thalidomide, an experimental drug. One such problem arises as to whether
a patient should be told of the seriousness of his illness; but does this discretion extend to
the use of new, experimental drugs? When a drug is very new and its effects on man can
not be properly assessed without human trials, researchers frequently obtain permission from
guardians of insane persons, or consent from long-term prisoners, to use them as guinea pigs.
Apparently, these human beings are given more consideration than the consuming public
who are given other new or experimental products without knowing any of the risks, suspected
or potential, in the drugs. Although the drug companies do not intend to use the con-
suming public as guinea pigs, this is often the result with drugs containing a harmful quality
which can not be discovered until after prolonged use. Neither the patients' inability to pre-
scribe for themselves, nor the doctors' freedom and responsibility to do what is in the patient's
best interest extends so far to make any man an experimental animal without his knowing it.
The American Medical Association is now in the process of promulgating a new series of
principles governing clinical investigation. These rules may serve as a standard which may
be helpful to the legal profession.
19. Senate Hearings, supra note 17, at 272.
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Where is the objectivity and fair representation required to uncover the
inherent dangers in a drug? This type of approach to development, test-
ing, manufacture and distribution results in an escalation of the number
of drug injuries.
The main question to be answered in suits of this type is that of
causal connection. As indicated previously, the effective cause is traceable
to a commercial rather than a scientific approach to marketing. Simple
tests on pregnant animals would have exposed the risk. Arrival at an
ultimate effective cause was initiated by a search for some common factor
among all these injuries. The mothers it was learned had all at one time
used thalidomide."0 Specific case studies and general comparisons of the
sales of the drug with appearances of phocomelia indicated the danger
period was limited to the first few weeks of pregnancy. During the early
stage of embryonic growth, the limb buds appear. The limbs apparently
are not affected by thalidomide if their development is beyond the six-
week stage; taking the drug before this time very often resulted in
phocomelia.2 ' The resulting injuries have led to several suits against the
manufacturer22 and there has been some report of settlements.23
The thalidomide suits present several novel legal problems. It has
been noted that the only danger from this drug is in the first few weeks
after conception. What then is the law on recovery for prenatal injuries?
Under what circumstances can a child recover for injuries inflicted before
birth?
Recovery for Prenatal Injury.-Until recently, the weight of author-
ity favored the common law view that, absent a statute to the contrary, an
20. At this point, the suspected drug should have been removed from the market; however,
this was not done until the drug was more than just under suspicion. But within a few weeks
after it was suspected, thalidomide was withdrawn. Taussig, supra note 14, at 1109. The drug
was removed from the market in November 26, 1961.
The singular effectiveness of thalidomide as a sedative or tranquilizer was well established
before its hazards were discovered; it was virtually impossible to commit suicide with it even
by swallowing huge quantities of the drug. There is great need for a drug with these
qualities. Nevertheless, numerous questions must be resolved before the drug can be released
for controlled use. For example, there may still be an undiscovered risk, such as an effect on
male users. Lutwak-Mann, Observations on Progeny of Thalidomide.Treated Male Rabbits,
1 BRISH MEDICAL J. 1090 (1964).
Hopefully, the possibility of a residual effect of thalidomide upon future pregnancies will
be studied. However, safer but equally effective substitute drugs may be found in the interim.
Again, the Food and Drug Administration may have to balance the benefits and the risks
of this drug.
21. Taussig, supra note 14; but see Apgar, Drugs and Pregnancy, 190 A.M.A.J. 840-41
(1964), where it is indicated that only 20% of the mothers taking thalidomide during the
danger period had abnormal babies.
22. Thalidomide Maker is Sued by Parents of Deformed Twins, N.Y. Times, Oct. 19, 1962,
p. 33, col. 1.
23. 6 Personal Injury Newsletter 189 (Feb. 10, 1964). An additional side effect injury
occurring in adults is termed periperal neuropathy. One Virginia case involving this injury
has been settled.
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infant has no right of action for injuries sustained by him en ventre sa
mere; however, the modern trend seems to be in the other direction.
Those courts adhering to the common law rule give several reasons in
support of this approach to prenatal injuries. First, it is said that there
can be no recovery because the child is a part of the mother and has no
separate legal existence which can be injured. 4 Second, it is stated by
some authorities that if recovery for prenatal injuries were allowed, there
is no reason why an infant could not sue its own mother for injuries
caused by the mother's negligence before giving birth.25 A third reason
is based on the practical difficulty of finding reliable proof to establish
causation. 6 On the other hand, the modern view argues: (1) that the
embryo is a part of the mother only in the sense that it lives within her
and obtains its nourishment there - it is a separate biological unit;2"
(2) that natural justice demands recognition of the legal right of the
child to begin life unimpaired by physical or mental injuries resulting
from a prenatal injury;2" and (3) that the law recognizes the existence
of an unborn child in other areas and ought to apply the same principles
in tort law. For example, in the area of pretermission, the right of in-
heritance of after-born children is protected. The policy supporting the
law in this area is so strong that even if a decedent leaves a will, a pre-
termitted child cannot be excluded from a share unless there is a clear
intention to do so in the will. 9 The "non-existent" child is also recog-
nized in criminal law where certain types of abortion are made a crime."
Fortunately, in tort law most courts are moving toward a view which
is responsive to the scientific fact that an unborn child has some form of
existence. The modern view is that a right of action does exist,3" though
it has been limited to cases in which the child can be said to be viable,
i.e., able to exist outside the body of the mother 2 A fetus may become
viable roughly between the twenty-fifth and twenty-eighth week of intra-
uterine life. 3 Some courts have said that "quickness" in the womb can
24. Stanford v. St. Louis-San Francisco Ry., 214 Ala. 611, 108 So. 566 (1926).
25. Allaire v. St. Luke's Hospital, 184 Ill. 359, 56 N.E. 638 (1900), overruled, Amann v.
Faidy, 415 Ill. 422, 114 N.E.2d 412 (1953).
26. Bliss v. Passanesi, 326 Mass. 461, 463, 95 N.E.2d 206, 207 (1950).
27. Kelly v. Gregory, 282 App. Div. 542, 125 N.Y.S.2d 696 (1953).
28. Bliss v. Passanes, 326 Mass. 461, 95 N.E.2d 206 (1950).
29. E.g., OHIO REV. CODE § 2107.34 (Supp. 1964); see Twtchell v. Alexander & Liggett,
115 Ohio App. 51, 184 N.E.2d 421 (1961).
30. See Verkennes v. Cormea, 229 Minn. 365, 38 N.W.2d 838 (1949).
31. Damasewcz v. Gorsuch, 197 Md. 417, 79 A-2d 550 (1951); Smith v. Brennan, 31 NJ.
353, 157 A.2d 497 (1960); Woods v. Lancet, 136 N.Y.S.2d 492 (Sup. Ct. 1954).
32. Wendt v. Lillo, 182 F. Supp. 56 (N.D. Iowa 1960); Hall v. Murphy, 236 S.C. 257, 113
S.E.2d 790 (1960).
33. See generally, MONTAGU, PRENATAL INFLUENCES 328 (1962)
Drugs administered to the pregnant mother at any time during the pregnancy are
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be the point in time when there is legal existence. 4 A few courts have
even held that recovery will be permitted for prenatal injury tortiously
inflicted at any time after conception, provided the child was born alive.3"
However, no court has gone further than conception and considered in-
jury to the sperm or ova. Where the child is born dead, there is a split
of authority on whether an action will be allowed, but some courts have
allowed a personal representative to recover on behalf of the next of kin."
In those jurisdictions which have not yet carried recovery back to con-
ception, the thalidomide cases may make new law The causal relation-
ship is dear, even though the exact mechanism which off-balances the
fetal growth is not yet understood. The line of recovery in prenatal in-
juries must necessarily be extended with thalidomide, since the only dan-
ger so far demonstrated is in the first few weeks of pregnancy If the
other legal and causal factors are met, it is hard to imagine a court refus-
ing to extend this "line" back to or near conception in order to cover
thalidomide injuries.
Mer/29
Mer/29, or triparanol, is a drug which was developed to control cho-
lesterol in the blood by inhibiting its biosynthesis.37 Among the unin-
tended side effects are cataracts, alopecia (hair loss), and ichthyosis
(dry harsh skin with adherent scales) Instructions accompanying the
drug warned against the possibility of liver damage and side effects of
nausea, vomiting, temporary vaginal bleeding, dermatitis, and thinning of
the hair.38 Warnings against use during pregnancy were also included.
In many cases, these warnings were not adequately conveyed to the user."9
However, not all of the pending suits are based on injuries specifically
covered by the warnings.
Negligence need not be a troublesome factor in the Mer/29 cases
for two reasons. First, the manufacturers violated FDA rules regarding
likely to be harmful to the fetus. Drugs that produce no apparent effect upon
the pregnant mother may produce very appreciable effects upon the fetus. The
two are interdependent but quite different physiological systems. The failure to
recognize this simple fact can be catastrophic.
See Amann v. Faidy, 415 Ill. 422, 114 NXE.2d 412 (1953).
34. Quickness refers to a heart beat or fetal movements which appear in three to four months.
Porter v. Lassiter, 91 Ga. App. 712, 87 S.E.2d 100 (1955)
35. Dailey v. Meier, 33 ill. App. 2d 218, 178 N.E.2d 691 (1961) (one month pregnant);
Smith v. Brennen, 31 N.J. 353, 157 A.2d 497 (1960) (injury seventy-five days before birth)
36. Amann v. Faidy, 415 ill. 422, 114 N.E.2d 412 (1953)
37 Flexman, MER/29 (Triparanol) and Cataract, Med. Trial. Tech. Q. 11 (Dec. 1963)
38. Id. at 16.
39. The warnings and instructions are sent with the drug to the administering physician
as well as the pharmacist. Exercising his professional judgment, the doctor will tell the pa-
tient as much or as little of these warnings as he deems important.
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disclosure of adverse test results and were subject to criminal sanction.4
Second, some adverse effects appeared while the drug was being tested,
but in spite of this the drug was released for public consumption in utter
disregard of the public good.41
Parnate
Parnate, or tranylcypromine sulphate, is used to relieve symptoms of
mental depressive reactions.4 This drug illustrates a unique problem in
that it must be used for a long enough period to permit the accumulation
of a sufficiently large number of cases before uncommon but serious side
effects become apparent. Shortly after Parnate was approved in 1961, a
few users suffered sudden and severe rises in blood pressure. Medical
literature reports the following injuries:
A severe reaction to tranylcyprommne (Parnate) sulfate has been char-
acterized by intense headache, nausea, vomiting, photophobia, sweating,
pallor and mild hypertension Most of the pauents have made a
spontaneous recovery, but death, usually associated with mtercranmal
hemorrhage, has occurre 43 %
Mechantsm of Injury.-Some persons, injured while using Parnate,
were found to have consumed cheese prior to suffering hemorrhages,
while others were using different drugs at the same time they took Par-
nate, e.g., amphetamines, reserpine, and certain diuretics. Parnate func-
tions through its effect on the monoamine oxidase (MAO) enzyme sys-
tem, one of the enzyme systems which serve to dissolve certain drugs and
40. Loory, Hid Drug Danger, Firm Gets Top Fine, N.Y. Herald Tribune, June 5, 1964,
p. 1, 14 col. 1; Drug Maker Fined $80,000 in Failure to Tell of Danger, N.Y. Times, June
5, 1964, p. 11, col. 1. The civil action based upon violations of a criminal statute will be
discussed later. See generally Annot., 79 A.L.R.2d 301 (1961).
41. Flexman, op. cit. supra note 37. The wilful or wanton character of defendant's conduct
will often negate the effect of any contributory negligence as well as provide a basis for purn-
tive damage claims.
It is estimated that there were 400,000 to 500,000 users of the drug distributed through-
out 45 states. Although it was marketed around the world, there is no information available
as to foreign law suits. The drug company reported 3,000 injuries; the cases pending involve
about 600 injured users. Hearings on Interagency Coordination in Drug Research and Regu-
lation before the Subcommittee on Reorganizaton and International Organizations of the
Committee on Government Operations, 88th Cong., 1st Sess., pt. 4, at 1955-78 (1963).
42. Leonard, Gifford, Williams, Tranylcypromme Sulfate Therapy, 187 A.M.A.J. 957-58
(1964).
43. Id. at 958. Letters were sent to doctors on October 9, 1963, warning of the danger to
persons with confirmed cerebral vascular or cardio-vascular defect or disease. A recent fact
sheet distributed by the FDA reported that since April of 1961, there were 430 cases of
arterial hypertension with cerebral reactions. U.S. Dept. of Health, Education, and Welfare,
Food and Drug Admmstration, Washington, D.C., Parnate Fact Sheet, March 16, 1964.
Among these were 50 cases of "cerebral vascular accidents" and 15 or 16 fatalities among
users of Parnate. The drug was withdrawn after protest and a hearing requested under §
505(e) of the Federal Food, Drag and Cosmetic Act. 76 Star. 781 (1963), 21 U.S.C. §
355(e) (Supp. V, 1964).
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foreign compounds. One of the foreign compounds is tyramine, a sub-
stance found in cheese. Unless controlled by the MAO enzyme system,
tyramine tends to greatly increase blood pressure unless its usually rapid
inactivation by monoamine oxidases is interfered with by inhibitors such
as Parnate. It is believed that when the action of the enzymes was
blocked by Parnate, the ingestion of certain blood pressure increasing
substances resulted in injury.44
In examining the causation in the Parnate injuries, one realizes the
extensive investigational program required to uncover risks.45  The
Food and Drug Administration has made Parnate available again, provid-
ing that adequate warnings are given for its use. 6 Several suits have
been filed alleging inadequate testing of the drug.
Sabin Poliomyelitis Vaccine
All of the foregoing drugs present unique legal and medical prob-
lems, but the Sabin Oral Vaccine is exceptional in this respect. The
problem here was the report of a very few cases of paralysis shortly after
the vaccine was administered. Was there any causal connection? Until
recently, polio was a particular problem only in civilized societies. In
less hygienic living conditions, most children at one time or another con-
tracted some mild form of polio that spread rapidly and immunized others
early in life. 8 With improved sanitation and cleaner living, less and
less children developed this natural Immunity. Albert Sabin succeeded
in isolating live polio virus particles that were "non-paralytic." Appar-
ently, this strain of virus particles was similar to the mild type which
Immunize most people at an early age. The Sabin vaccine was there-
fore developed to replace and improve upon natural immunity
For convenience, the three poliomyelitis types have been classified as
I, II, and III. A basic problem with all three polio viruses is their inabil-
ity to grow in most standard culture mediums. In addition to the human
body, which is the best medium for growth of polio viruses, monkey kid-
44. Goldberg, Monoamine Oxidase Inhibitors, 190 A.M.A.J. 456, 460 (1964)
45. Very often, long term experimentation on human beings is required before the exact
causes of injury can be determined. However, the law should afford protection to those in-
jured in the process. At the very least, trained and conscientious investigators should be used
to discover and help reduce the number of such injuries. Since the number of injuries from
any given new drug can be statistically predicted, the drug companies can easily be required
to spread the cost of compensating these injuries in advance, by requiring those who benefit
from the drugs to pay more.
46. Parnate Will Re-enter Market Under Revised Labeling, 19 FOOD DRUG CosM. L.J.
325 (1964).
47 Fulbright, $1 Million Sought Here In Drug Suit, N.Y. Herald Tribune, March 26,
1964, p. 7, col. 1.
48. WILSON, op. cit. supra note 9, at 40: "In other words, modern hygiene, by protecting
children from the mild attacks of infancy, which hardly ever affected nerves, had left them
unprotected by immunity in adult life."
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ney tissue was also found stutable4 Using this medium, scientists worked
toward "cleaning up" the virus so that it could be presented in vaccine
form. There were several unsuccessful attempts by other scientists be-
fore Sabin's vaccine was finally approved." The attenuated or non-para-
lyric virus particles were obtained by growing the virus in monkey kidney
tissue. The virus was "passed through" these cultures and the safest
strains selected. Scientists searched for strains which produced no notice-
able sickness, adequate Immunological response, and no paralysis.
Developing an immunity to polio with the Sabin vaccine contem-
plated a growth of the virus particles in the intestinal tract. By directly
injecting the virus into the brains and spinal cords of monkeys, scaentists
were able to study the activity of the virus under more stringent condi-
tions than that required for man." It was hoped that the virus would
never get to man's nervous system.
With this type of immunological process, it is possible for one who
did not take the Sabin vaccine to be infected by another who did take it.
The virus, multiplying in the intestines for weeks or months, passes out
of the system in the feces thereby creating the possibility of Infection in
others.5" In other words, the live vaccine actually gives the user an active,
persistent, and contagious case of polio.
There was much concern over the danger of Infection of one who
did not take the Sabin vaccine by one who did. This contact case may
in turn spread the disease through a series of other persons. In this fash-
ion, the process of obtaining a safe virus may be reversed, thus selecting
out wilder strains in a human culture medium. The question then arises
as to whether these contact cases may result in paralysis from a reverted
wild form of virus. 3 There is still some question on this point. Essen-
49. Ramos-Alvarez & Sabin, Intestinal Viral Flora of Healthy Children Demonstrable by
Monkey Kidney Tissue Cultures, 46 AM. J. PUB. HEALTH 295 (1956).
50. WILSON, op. cit. supra note 9, at 224-34. Much debate was stimulated over which of
the available vaccines should be used - Salk or Sabin. The Sabin vaccine was more con-
venient, but serious questions were raised concerning its reliability. Sabin's vaccine was said
to give longer and more complete protection although many felt more secure with a dead
vaccine (Salk) that was not growing and could not change. WORLD HEALTH ORGANIZA-
TION, PAN Am cCAN HEALTH ORGANIZATION, L-rV PoLIovmus VACCINES: SECOND
INTERNATIONAL CONFERENCE ON LIVE POLIOVIRUS VACCINES (Pan Am. Health Org.
Science Publ. No. 50 1960) [hereinafter WHO]. The live vaccine could be swallowed on
candy, while Salk's dead vaccine had to be injected with a syringe.
51. Sabin, Behavior of Chimpanzee - Avirulent Poliomyelitis Viruses in Experimentally In-
fected Human Volunteers, 68 TRANSACTIONS OF THE Ass'N OF AM. PHYSICIANS 64-72
(1955).
52. Gelfand, LeBlanc, Potash, Clemmer, Fox, The Spread of Living Attenuated Strains of
Polioviruses in Two Communities in Southern Louisiana, 50 AM. J. PuB. HEALTH 767
(1960); Gelfand, Potash, LeBlanc, Fox, Intrafamilial and Interfamilial Spread of Living Vac-
cine Strains of Polioviruses, 170 A.M.AJ. 2039 (1959).
53. Sabin, Characteristics and Potentilities of Experimentally Produced and Natarally Oc-
curring Varients of Poliomyelitis Virus, 61 ANNALS OF N.Y. AcADEmY OF SCIENCES 924
(1955); Melnick, Problems Associated With Use of Live Poliovirus Vaccine, 50 AM. J. PUB.
HEALTH 1013 (1960).
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tially, reversion presents a problem of stability. There is concern that
the virus will not remain homogenous in that it will become wild as it
passes from one individual to another. Other questions raised were:
(1) how many persons can the original attenuated virus pass through be-
fore it reverts to "neurovirulence", (2) were all "bad" polio virus par-
ticles removed or was there just a mixture which was predominantly at-
tenuated; (3) can some of the non-paralytic particles become "bad" as
they grow and multiply in the person who took the vaccine (mutation),
(4) are there any undiscovered viruses in the vaccine which can cause
different illnesses;54 (5) how long does Sabin immunity last; (6) are
there enough people unprotected by either Salk or natural immunity to
make the risk of a mass program worthwhile; (7) how serious is the
interference of other intestinal viruses with the growth of Sabin's virus;
and (8) do all people have the same resistances, z.e., will the attenuated
virus grow just in the intestinal tract of all people or, in some, spread to
the blood (viremia) and nervous system (paralysis) ?
Mass Immunzzation.-These and other questions stimulated skepti-
cism as to whether the whole program was not being hurriedly con-
ducted.55 Serious questions of whether the risks involved would be mini-
mized enough to make a mass program advisable were raised. As men-
tioned, a major concern was the possibility of reversion; however, in time,
most of these questions were answered and the drug was approved.5" It
was felt that the chance of reversion through a series of contact cases
could be averted. This would be accomplished by urging as many peo-
ple as possible to take the vaccine. "It seems that the surest way to initi-
ate the use of live virus vaccine in this country would be on a mass basis
so that the entire population in a community receives the vaccine virus
simultaneously, thus lessening the number of susceptibles who might be-
come infected with reverted virus.
57
The American people had to be convinced of the wisdom, safety, and
public responsibility involved. It was a "Wipe Out Polio Forever" cam-
54. WORLD HEALTH ORGANIZATION, REQUIREMENTS FOR BIOLOGICAL SUBSTANCES 6
(WHO Tech. Rep. Ser. No. 237, 1962)
55. WHO, op. cit. supra note 50.
56. Terry, U.S. Dept. of Health, Education and Welfare, The Association of Cases of Polio-
myelitis With The Use of Type III Oral Poliomyelitis Vaccine, p. 2 (Sept. 20, 1962) Type
I was licensed for distribution on Aug. 17, 1961; Type II on Oct. 10, 1961; and Type III on
March 27, 1962. Prior to these dates, experimental lots of the respective vaccines were em-
ployed in a number of small scale and some large scale community programs.
57 Melnick, Population Genetics Applied to Live Poliovirus Vaccine, 52 AM. J. OF PUB.
HEALTH 472, 482 (1962).
In Russia, the problem was relatively easy in that people had little choice in the matter
and were more easily directed to take the vaccine. Sabin, Poliomyelitis Incidence in the Soviet
Union in 1960, 176 A.M.A.J. 231 (1961) The results of large scale Russian experiments
were carefully studied before the FDA approved the vaccine for use in the United States.
WHO, op. cit. supra note 50.
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paign. The program was to be a triumph for science and epidemiology,
erasing the poor image which followed the Cutter injuries. In order to
encourage mass participation the vaccine was generally made available
without charge. This situation presents the seed of the legal problems.
In these mass participation programs, there was, in effect, a blanket war-
ranty of merchantability in order to persuade everyone to take the vac-
cne; yet the vaccine was usually offered without charge. Hence no sale,
usually associated with warranties, was involved. Two problems arise
which will be considered in detail. (1) whether there are sufficient causal
links present to justify a law suit; and (2) whether warranty may be
alleged without a sale.
With respect to causation, the polio vaccine cases are not as easily
resolved as the thalidomide and Parnate cases. No interfering prod-
uct such as cheese was found as was the case with Parnate, nor was the
paralysis associated with any special physical condition of the drug user
as was the case with thalidomide, %.e., pregnancy. A common explanation
for the paralysis was that the patient was nurturing the wild community
virus at the time he received the attenuated vaccine virus.5" One major
difficulty with this explanation and the entire causation problem in the
polio vaccine cases is the fact that relatively few people were really para-
lyzed. Medical literature suggests many reasons for the few cases of paral-
ysis,"9 but studies have been unable to explain away all the cases. The
unexplained cases are lumped together under the term "compatible." In
this context, the term "compatible" imports consistency with a vaccine
cause. Tests and standards have been developed for determining the de-
gree of compatibility,' but the causal ties are neither as dear nor as con-
clusive as with other drug injuries."' However, in the most recent medical
literature, there appears to be a shift in attitude." The Public Health
58. Sabin, Is There an Exceedingly Small Risk Associated With Oral Poliovirus Vaccine?,
183 A.M.A.J. 268 (1963).
59. Ibud; Wehrle, Leedom, Portnoy, Pierce, Cowper, Safety of Sabin Oral Poliomyelitis Vac-
cine Strain, 186 A.M.A.J. 821 (1963).
60. The Poliomyelitis Surveillance Committee has prescribed a number of standards based
on knowledge of the incubation period and vaccine characteristics, such as antibody response,
marker tests, the type of virus isolated, and the type of paralysis. Final classifications used
were probable, improbable, uncertain, and excluded.
61. Gelfand, Oral Vaccine: Associated Paralytic Poliomyelitis, 1962, 184 A.M.AJ. 948, 949
(1963), reads as follows:
Because OPV [Oral Poliomyelitis Vaccine) produces active infection which stim-
ulates the natural process, we expect to find the virologic and serologic evidence
indicative of current infection in recent vaccinees. When this evidence is accom-
panied by paralytic illness, we have only limited means of assaying the relationship
of the two events in the individual. An aggregate of cases which are individually
inconclusive may, however, have epidemiologic characteristics and consistent lab-
oratory findings which would either suggest or tend to rule out vaccine as the
etiologic agent.
62. A series of articles appeared on Oct. 5, 1964: Henderson, Witte, Morris, and Langmuir,
Paralytic Disease Assocated With Oral Polio Vaccines, 190 A.M.A.J. 41 (1964); Special
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Service has recognized that some of the compatible cases were probably
caused by the vaccine. The problem is in stopping the growth and spread
of the virus into the blood and nervous system. A suggestion which has
appeared several times is that the Sabin vaccine should be used in connec-
tion with the Salk vaccine, i.e., immunize the gastro-intestinal tract
(Sabin) after the dead vaccine (Salk) has been used to raise the antibody
titer level of the blood.
In a same series of articles on Sabin Poliomyelitis Vaccine published
in the Journal of the Amercan Medical Association, the number of so-
called compatible cases is now said to total fifty-seven, although reports
of suspected vaccine injuries are far more numerous.63 There is even a
report of some household "contact" cases. The Advisory Committee rec-
ommended changes in emphasis in this report, stressing immunization of
infants and pre-school age children."4
Since type II Oral Poliomyelitis Vaccine is believed to give some pro-
tection to the "slight" but now recognized risk in types I and III, the com-
mittee recommends that type II be given first. In the same series of arti-
cles, Dr. Sabin replies to this new position. 5
PRACTICAL LIMITATIONS
Since the use of drugs often involves a matter of life and death,
there is great public interest surrounding even experimental drugs. How-
ever, advancement requires use. The benefits of new drugs are studied in
relation to other drugs available, as for example Sabin with Salk, and then
balanced against the risks. In contrast to the benefits and risks are policy
considerations, z.e., the demand for new drugs, freedom to compete in a
large and growing market, and the desire to give maximum value, pro-
tection, and safety to drug consumers. However, it is extremely difficult
to balance the potential good against an unknown level of risk, even in
Report of Advisory Committee of the Public Health Service, Oral Poliomyelitis Vaccines, 190
A.M.A.J. 49 (1964); Sabin, Commentary on Report of Oral Poliomyelitis Vaccines, 190
A.M.A.J. 52 (1964)
63. The most reliable statistics appear to be those of the Public Health Service, Poliomyelitis
Surveillance Committee, but they cover only the most serious injuries. Many other people
complained of sickness probably associated with the mild disease which the vaccine was sup-
posed to create.
There are over a dozen Sabin cases now pending. At the time of this printing, one Sabin
suit has been won with a verdict for the plaintiff for $120,000.00. Polio Victim Gets $120,-
000.00, Oklahoma City Times, Nov. 19, 1964, p. 6, col. 1. In two Oregon suits, one ended
with a decision for the defendant, the other in a mistrial. The Oregonian, Feb. 27, 1965, p.
13, col. 1.
64. Special Report, supra note 62, at 50.
65. Sabin, supra note 62. Dr. Sabin admits that most adults do not need to take the oral
vaccine because they are already naturally immune, but he emphasizes that there is no easy
way of identifying those who are not immune. Consequently, he points to the "demonstrated
superiority" and "lack of positive evidence of contraindications" as reasons in favor of mass
use of his vaccine. Id. at 54.
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light of public necessity. Choosing informed decision makers is vital.
Certainly, some controls and assurances of uniformity are required at that
level. The essential question is how to protect the consumer without
restricting medical progress. Informed consent on the part of the
eventual user has been one answer, unproved testing another," and
insurance" still another.
Discussing thalidomide in a recent periodical, one author recognized
part of the problem:
This [drug] forcefully calls attention to possible serious effects of new
drugs on the fetus as a result of use during pregnancy. It poses the
problem of what constitutes adequate clinical studies to detect this
potentiality.69
More control over the manufacture, testing, and use of drugs is sug-
gested by the types of injuries and trade practices discussed earlier, yet
one author writes that "the public policy historically applicable to medi-
cine in this country has been to preserve substantial freedom in medical
practice." But the size and complexity of today's society requires some
control over, or cooperation among, drug companies so as to insure uni-
form standards of safety and effectiveness.
In a recent article discussing the practical problem of industry compe-
tition, it is said that public demand and industry competition urge rapid
marketing of new drugs.71 Furthermore, the productivity of the drug
industry creates a situation wherein it becomes more difficult to thorough-
ly investigate all drugs. Trained and objective investigators are often
scarce for the more mundane drugs, although "wonder" drugs are much
more likely to stimulate interest and cooperation. This scarcity of quali-
fied investigators results in erroneous decisions with respect to marketing,
and the accumulation of inadequate, data to support advertising claims
for new drugs.' When the decision is made to market a drug, "there can
be no wishy-washy approach-to its promotion' 73 Therefore, most drug
advertisements are more persuasive than educational. On the other hand,
drug houses are reluctant to spend time and money in routine toxicity
testing, unless the drug shows promise, z.e., until the first human tests
are encouraging. Thus, human tests may be pushed ahead of animal
66. Maericklen v. Smith, 129 Colo. 72, 266 P.2d 1095 (1954)
67. Lasagna, Problems of Drug Development, 145 ScIENcE 362 (1964).
68. 2 FRUNMR & ftiuMAN, PRoDucTs LIABILITY 5 50, at 1101 (1960).
69. Smith, New Drug Applications, 17 FooD DRUG COSM. L.J. 497, 501 (1962)
70. Ringuette, Authority, Drugs and the-Practice of Medicine, 16 FooD DRUG COSM. LJ.
393, 408 (1961).
71. Lasagna, supra note 67; see also-MacDonald and MacKay, Adverse Drug Reactions, 190
A.M.A.J. 1071 (1964); Modell, Safety in New Drugs, 190 A.M.J. 141 (1964)
72. Lasagna, supra note 67, at 363.
73. Id. at 364.
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testing. In this regard, it is said that animal testing should be required
by law before extensive field trials are allowed.74 At the present time,
the Food and Drug laws provide some protection in that the Secretary
may require preclinical animal testing."
Platntiff's Attorneys Groups
For the lawyer, all of the foregoing discussion of drugs and drug
problems means many more valuable hours spent in medical research.
The complexity of the subject matter represents important practical
problems which necessarily call for the aid of a consulting expert. Find-
ing specialists who are conversant with a particular drug is difficult in
itself. In addition, a jury of laymen must be made to understand vast
technical problems and decide issues upon which even the most learned
disagree.
In meeting these difficult problems, plaintiff's attorneys have re-
cently been banding together. The first "group" to be organized was
the Mer/29 group in 1963. Thirty-five lawyers met in Chicago en-
visioning a cooperative effort in the preparation of their cases both
legally and medically. Presently, there are 230 lawyers and law firms
in this group, representing five hundred to six hundred cases. 6
The work done by the groups is general in scope, %.e., each lawyer
handles his own pleadings, settlement, and trial. However, assistance is
74. Letter from the Pharmaceutical Manufacturers Association to the writer, Aug. 1, 1962.
75. Federal Food, Drug and Cosmetic Act § 505 (i), 76 Star. 781 (1963), 21 U.S.C. 355 (i)
(Supp. V, 1964).
Although most reputable companies conduct some animal tests, they continue to
object strenuously to all new impositions whether legislative or judicial. The claim
is made that manufacturers, with the specter of liability present, may tend to diminish both
the quality of testing and development of new drugs. Gibson, The Effect of the Investsga-
tuonal Drug Regulations on Drug Research and Development, 19 FooD DRUG CoSM. LJ.
153 (1964); Comment, Strict Liability for Drug Manufacturers: Public Policy Misconceived,
13 STAN. L. REV. 645, 649 (1961) In reality, this "hue and cry" about increasing costs
and adverse effects is a mere shibboleth. One has only to examine the annual financial re-
ports of the drug companies to discover how small liability looms in the profit growth picture
of the industry. Hearings Before the Subcommittee on Reorganization & International Or-
ganizations of the Committee on Government Operations, 88th Cong., lst Sess., pt. 4, at
1955-78 (1963). The 1962 amendments are themselves an attempt to correct unfair trade
practices uncovered by the Kefauver Committee. The effort is towards quality, safety and
understanding. Special Announcement, New Book on Drugs - 1965, 190 A.M.A.J. 206
(1964).
Although NND [New and Nonofficial Drugs] proved useful to many as a refer-
ence book, the rapid introduction of a large number of new drugs has made it in-
adequate to meet the needs of practicing physicians.
The NND is being replaced with a new book entitled New Drugs. The contents are oriented
to fit the needs of the practitioner and the information is said to be objectively presented.
See generally, Coggeshall, Drug Safety and Drug Control, 3 J. NEw DRUGS 147 (1963);
Meyers, The Food & Drug Administration's Role in the Testing of New Drugs, 3 J. NEw
DRUGS 338 (1963).
76. Hearings Before the Subcommittee on Reorganization & International Organizations
of the Committee on Government Operations, 88th Cong., 1st. Sess., pt. 4, at 1955-78 (1963)
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available through the group at the trial stage if requested. The activities
of the group involve the taking of depositions, discovery of documents,
medical and legal research, and news reporting on trials. Most important
is the handling of medical experts. They are consulted by representa-
tives of the group and the results are made available to all. Harassment
of experts by hundreds of attorneys is avoided and as a result the few
experts available on individual drugs are more inclined to cooperate by
supplying information or witnesses.
The Mer/29 group provided the pattern for three other groups in-
volved with Enovid, Sabin, and Aralen. The Enovid group is one of
the newest; only a few cases have been filed. No group is yet organized
for Parnate.
7
The advantages of group efforts are obvious. First, the pooling of
information is an attempt to gain an even advantage with the defendant
who, as a rule, has access to all the facts of all cases. Second, there are
economic savings in that the work is done just once for all cases. Third,
it is felt that by grouping efforts the legal issues in these cases can be
raised more clearly. As a result, there is likely to be an increase in the
number of appellate opinions concerning drug products.
Although the group approach has been highly successful, it is ma-
portant to note that there are significant limitations to such efforts.
Only products which cause wide-spread and contemporaneous harm are
adaptable to the nation-wide "group" approach. Since the main ad-
vantage of this system is in helping the attorneys to prepare, it would
be somewhat limited to situations where all are preparing at approx-
mately the same time. In addition, since much of the progress of, and
advantage from, these groups comes from negotiation rather than litAga-
tion, cooperation of the manufacturer and its insurer is vital.
The group system represents a movement toward more equal justice.
The public can anticipate the appearance of more such groups as lawyers
seek to better their preparation, reduce costs, and properly represent the
injured client. With some understanding of the drugs, the injuries com-
plained of, the problem of causation, and the other pressures upon drug
researchers, manufacturers, and attorneys, the changing legal picture can
now be drawn.
MISR1PRESENTATION
Although negligent conduct can sometimes be shown, the major
reliance in new drug cases is on the legal aspects of misrepresentation;
but this is a nebulous term. It appears in connection with many actions
77. No figures are yet available for the number of Parnate cases arising before the new labels
were ordered.
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such as deceit, fraud, warranty, and so on."8 Because the courts do not
agree on the exact nature of these actions, any attempt to distinguish be-
tween them is necessarily oversimplified and partly Inaccurate.
Notwithstanding this confusion, it is necessary for purposes of proper
analysis to examine the traditional approaches to this subject. There is
no better starting point than Dean Prosser's analysis. He states that ams-
representation runs all through the law and has been merged indistin-
guishably with all kinds of misconduct."0 Attempts to treat msrepresen-
tation as a distinct cause of action in tort has caused confusion with the
common law action of deceit. Misrepresentation is broader than deceit,
deceit being only one part of a familiar scheme in tort law In other
words, misrepresentation may include (1) an intent to deceive (deceit),
(2) negligence (negligent misrepresentation), and (3) statements made
under circumstances which give rise to a policy of strict liability, as for
example through warranty. 0
Although deceit is available and has been used in drug cases,8 ' it
has limitations. There are two elements in this action which are difficult
to prove: (1) scienter, or a knowledge or belief on the part of the defend-
ant that the representation is false; and (2) ntenton to induce the plain-
tiff to do or refrain from doing some act in reliance upon the misrepre-
sentation. In many drug liability cases, the representation is innocently
made and therefore the case cannot rest upon deceit. Consequently, con-
cern here is with warranty and negligent misrepresentation. The latter form
of misrepresentation is rarely used, but because of its appearance in the
new drug cases it deserves some explanation. A case brought under a
theory of negligent misrepresentation requires no proof of an inteutzonal
misstatement. Instead, the plaintiff need only show that the representa-
tion from which the product-caused injury is alleged to have flowed was
one that an ordinarily careful man would not have made under the cir-
cumstances.8 2 The representation may be negligent because of the man-
ner of expression, 3 or because of the type of business involved.84 That
is, if the person who makes the representation does so in the course of a
business or profession of supplying services which require special com-
78. Bohlen, Misrepresentation as Deceit, Negligence, or Warranty, 42 HARV. L REV. 733
(1929); Carpenter, Responsibility for Intentional, Negligent and Innocent Misrepresentation,
24 ILL. L. REV. 749 (1930), Smith, Liability for Honest Misrepresentation, 24 HARv. L
REV. 415 (1911).
79. PROSSER, TORTS § 100, at 697-98 (3d ed. 1964).
80. Id. at 698.
81. Wennerholm v. Stanford Univ. School of Medicine, 20 Cal, 2d 713, 128 P.2d 522
(1942).
82. Cunningham v. C. R. Pease House Furnishing Co., 74 N.H. 435, 69 Ad. 120 (1908)
83. See Nash v. Minnesota Title Ins. & Trust Co., 163 Mass. 574, 40 N.E. 1039 (1895)
84. See Toth v. Vazquez, 3 N.J. Super. 379, 65 A.2d 778 (1949); Ultramares Corp. v.
Touche, 255 N.Y. 170, 174 N.E. 441 (1931).
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petence, he should have the competence thus professed. 5 The basis of
this liability is the reliance of the consumer upon the qualifications of one
who has a particular profession, talent, skill, or knowledge.
There is a series of product cases where negligent misrepresentation
was the basis for liability;86 but there is still authority supporting applica-
tion of this doctrine only in cases where there has been an invasion of
interests of a financial or commercial character, %.e., in the course of busi-
ness dealings.8 7 There are also specific drug product cases which have
failed under this theory. One involved an anti-rabies vaccine.88 The
pamphlet accompanying the vaccine warned of a .04 percent risk of paral-
ysis and decedent was shown the pamphlet by the treating physician.
The court presumed that he had acquainted himself with the pamphlet
and had thus assumed the risk. 9 But the availability of contributory neg-
ligence and assumption of the risk may make negligent misrepresentatlon
uninviting, particularly in light of the fact that these defenses are not well
defined in this action. The standards for these defenses are complicated
in that negligence is based on words rather than acts.
In addition to the obstacle of negligence defenses, there is the difficulty
of establishing a standard of care for the person making the represen-
tations. Courts may very well find a lower standard for negligent
representations, because elaborate testing ought to minimize the risk up-
on which the standard may depend. But this argument is used to reduce
the standard for regular negligence actions in this field. The real source
of difficulty is the necessity of proving words instead of acts.
Proof that defendant knew or should have known of certain dangers
or adverse affects is an additional stumbling block. In the case of thali-
domide, this element of proof hinges on whether there is knowledge that
certain drugs can pass the placental barrier and produce various abnor-
malities or even abortions. Negligence would then arm in failing to test
the drug on pregnant animals, pretending that the drug was safe, and
assuring physician and patient that the drug could be used during preg-
nancy. In short, this involves mducing reliance on information which
the supplier did not know to be true. Perhaps the success of more cases
on the negligent misrepresentation action will stimulate a new concern
for knowing the truth before there is wide distribution of a drug.
85. SALMoND, TORTS § 501 (i1th ed. 1953).
86. Segal v. Carroll Furniture Co., 51 Ga. App. 164, 179 S.E. 775 (1935) (bed collapsed),
Andreottala v. Gaeta, 260 Mass. 105, 156 N.E. 731 (1927) (prescription filled incorrectly);
Holly v. H. L Green Co., 3 Misc. 2d 941, 155 N.Y.S.2d 197 (1956) (used soda fountain
exploded); Williamson v. Faxon, 208 N.Y. 108, 101 N.E. 799 (1913) (laxauve); ,Rulane
Gas Co. v. Montgomery Ward Co., 231 N.C. 270, 56 S.E2d 689 (1949) (hot water heater
explosion).
87 United States v. Neustadt, 366 U.S. 696, 711 n.26 (1961)
88. Carmen v. Eli Lilly Co., 109 Ind. App. 76, 32 N.E.2d 729 (1941).
89. Id. at 84, 32 N.E.2d at 731.
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STRICT LIABILITY
The discussion concerning strict liability is not concerned with
whether it should be applied to drug cases, but rather what forms it
should take when applied. Strict liability is, of course, liability without
fault. It can be inposed through warranty, by statute, or in tort.
Warranty
It has been noted that courts have blended deceit, negligent mis-
representation, and warranty9" Actions in deceit have been allowed
"for an honest but carelessly or unavoidably inaccurate statement."'"
This takes deceit into the field of negligence. With respect to war-
ranty, there has been a steady movement into the tort area; privity is
being dropped and negligence defenses have been added." More litiga-
tion in negligent misrepresentation may reverse these terms, thus confin-
ing deceit to intentional and conscious misrepresentation and reaffirming
privity and contract theories in warranty At this tune it can be said that
warranty is a specie of strict liability in that wrongful intent or negligence
on the part of the defendant need not be shown. The more difficult prob-
lems of proof will be examined in greater detail.
Sale.-Plaintiffs seeking to recover for injuries will, if warranty is the
basis for their action, experience some difficulty in overcoming the lack
of a sale. Some courts have denied any implication of warranty by
insisting on a technical sale.93 When the drugs are administered by a
physician in a course of treatment, the proof of a sale may be more diffi-
cult. This was the difficulty encountered when "no sale" was argued
in the Cutter and Perlmutter v. Beth David Hospital4 cases.
There are three ways in which the sale problem may arise: (1) ad-
ministration of the drug by a physician; (2) administration of the drug
during experimental drug testing; and (3) public distribution of vaccines.
The Cutter case answered the argument with respect to doctor adminis-
tered drugs. The court said: "Clearly, it is the patient and not the doctor
who is the ultimate consumer of the vaccine [The] implied warran-
ties run to the benefit of persons intended to be the consumers." 5
90. Bohlen, supra note 78.
91. Bohlen, supra note 78, at 733.
92. See Webster v. Blue Ship Tea Room, Inc., 198 N.E.2d 309 (Mass. 1964), noted in 16
W REs. L. REv. 454 (1965) (food case; fishbone in fish chowder) In the Blue Shtp case
the court seems to be recognizing the defense of assumption of the risk in a warranty action.
See generally Boshkoff, Some Thoughts About Physical Harm, Disclaimers, and Warranties, 4
BOSTON INDUST. & COM. L. REV. 285 (1963), where it is pointed out that the consumer gen-
erally demands perfection in drugs, but only average quality in cigarettes. If the exceptions are
deemed unreasonable, then as a matter of law there is contributory negligence.
93. Perlmutter v. Beth David Hosp., 308 N.Y. 100, 123 N.E.2d 792 (1954)
94. Ibid.
95. Gottsdanker v. Cutter Labs., 182 Cal. App. 2d 602, 609, 6 Cal. Rep. 320, 324 (19 0)
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In Perlmutter, during the course of hospital treatment, the plaintiff re-
ceived a blood transfusion which resulted in hepatitis. It was held that
the use of a blood serum was a service and not a sale. If there is no sale
then there is no liability in implied warranty." A statute has been en-
acted in another state to provide this exception for injuries resulting from
blood and serum use." Therefore, problems in proving a sale may be
encountered with the new drugs if they were given by a physician as part
of a continuing service as in a hospital.
The "experimental drug" aspect of the warranty cases is very new
It appears as though the thalidomide cases have been the first to raise
problems in this area. However, the legal problems here, at least with
respect to "sale," should be no different than doctor administered and ap-
proved drugs.
With respect to publicly distributed drugs, the Sabin vaccine presents
the most interesting problem. The Sabin program in most areas of the
country involved free distribution of live virus on sugar cubes or in little
cups of water. It was advertised as free to all, yet at the distribution cen-
ters a "donation" box was placed somewhere along the line. Often a sign
was posted suggesting "25 cent donations" or "donations of any amount."
For all practical purposes, everyone gave something. 8 The question then
arises as to whether there is a sale if one pays for a "free sample."
The Uniform Commercial Code may have some effect on the techni-
cal sale requirement. The UCC theory of liability does not rest on any
equitable notions of distributing the loss as appears to be the case with
some forms of strict liability. Rather, the code establishes several special
requirements as a basis upon which recovery may be had in warranty.
Imposing a requirement of a sale as a sne qua non of recovery seems un-
duly restrictive; however, section 2-313 may do just that. The section
speaks of "seller," "buyer," and "bargain." The definitions section of
the UCC, 2-106, purports to cover the entire sales article when it defines
a sale as the passing of title from seller to buyer for a price. Section
2-204 emphasizes the contractual basis of a sale. These sections may be
held to apply to the terms of 2-313 regardless of the official comment
which reads:
[T]he warranty sections are not designed in any way to disturb
those lines of case law growth which have recognized that warranties
96. Perlmutter v. Beth David Hosp., 308 N.Y. 100, 103, 123 N.E.2d 792, 795 (1954),
reads in part as follows: "[11f the transaction were to be deemed a sale, liability would attach
irrespective of negligence or other fault. The act of healing frequently calls for a balancing of
risks and dangers."
97. CAL. HEALT- & SAFETY CODE § 1623 (Deering 1961).
98. Berland, Doctor Sabr's 30 Year War With Polio, Today's Health, Sept., 1962, p. 54
(Cleveland, Ohio averaged 24.8 cents per donation).
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need not be confined either to sales contracts or to the direct parties
to such a contract.99
It has been noted that the rules governing sales warranties are ex-
tended by analogy to contracts for bailment and for labor and materials.' 0
By the same analogy, protection can certainly be extended to food and
drug products which are closer to "sale" than are bailments.
Prwty.-The application of the privity requirement has in the past
depended partly upon the nature of the product involved. Today, for ex-
ample, food cases are turning more on traditional strict tort liability than
negligence or warranty; however, courts often say no privity need be
proved, and an award is made on the basis of warranty.'
In the past, many fictions have been utilized to dispense with privity.
The warranty has been held to run with the goods0 2 or inure to the ulti-
mate consumer's benefit.0 3 Courts have used the third party beneficiary
theory' and have also held that the retailer's warranty from the manu-
facturer is assigned or extends to the ultimate consumer. 0 5 The tort
character of the warranty has either been stressed' or privity has been
plainly rejected.' Therefore, the trend of modern case law is away from
the privity requirement.'
99. UNiFoRM COMMERCIAL CODE § 2-313, comment 2 [hereinafter cited as UCC]. Cita-
tions are to the 1962 official text published by the American Institute and the National Con-
ference of Commissioners on Uniform State Laws.
100. Farnsworth, Implied Warrantes of Quality n Non-sales Cases, 57 COLUM. I. REV.
653 (1957).
101. An analogy to food products may bring these drug cases under the wing of protection
from the privity requirement which food cases enjoy. Crystal Coca-Cola Bottling Co. v.
Cathey, 83 Ariz. 163, 317 P.2d 1094 (1957) (fly in coke); Ward Baking Co. v. Trizzino, 27
Ohio App. 475, 161 N.E. 557 (1928) (needle in cake); Swift & Co. v. Wells, 201 Va. 213,
110 S.E.2d 203 (1959) (infected pork) Similarly, one could validly argue that drugs
whether injected, swallowed, inhaled, or rubbed on, are consumed. However, it is important
to realize that the basic similarity between food and drugs is not in the method of application
or consumption, or in its intimate connection with the body, but in the very essence of the
product itself. In this respect, the courts must look at who has control over the product
(opportunity to discover defects), the normal expectations of people regarding the product,
and the nature and importance of the product in relation to health, sustenance and normal
needs of the human body. Drugs are as important as food in these respects.
2 FRUMER & FRIEDMAN, PRODUCTS LIABILITY § 33.02(2); but see id. § 16.03 (4) (a), at
386 (1961)
102. Coca-Cola Bottling Works v. Lyons, 145 Miss. 876, 111 So. 305 (1927)
103. Klein v. Duchess Sandwich Co., 14 Cal. 2d 272, 93 P.2d 799 (1939)
104. Ward Baking Co. v. Trizzino, 27 Ohio App. 475, 161 N.E. 557 (1928)
105. Madouros v. Kansas City Coca-Cola Bottling Co., 230 Mo. App. 275, 90 S.W.2d 445
(1936)
106. Mazetti v. Armour & Co., 75 Wash. 622, 135 Pac. 633 (1913)
107 UCC § 2-318; see also Crystal Coca-Cola Bottling Co. v. Cathey, 83 Ariz. 163, 317
P.2d 1094 (1957) (food case)
108. In Hennsngson v. Bloomfield Motors, Inc., 32 N.J. 358, 161 A.2d 69 (1960), there
was an injury caused by a defective automobile. Lability to third persons was established
through implied warranty as it was through negligence in MacPherson v. Buick Motor Car
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The drug cases are part of this trend. The Cutter case, for example, dis-
pensed with privity, holding that the policy favoring drug companies and
freedom for them is not warranted where the drug actively caused the
disease it was designed to prevent" 9 The privity requirement should not;
however, rest solely on a "policy" of protecting the manufacturer. The
Cutter case, after establishing this policy as the basis for the retention of
privity, abrogated it by simply demonstrating the serious nature of the
injury. When a drug's reaction is exactly opposite from that intended,
no policy favoring manufacturers ought to save them from liability by
application of an outworn technicality such as privity.
One might distingtush cases involving drugs which only failed to cure,
or vaccines which failed to protect, from cases which caused "side-effects."
Side-effect injuries are not the type contemplated in Cutter where the
court dispensed with privity. Therefore, unless the injuries caused by
Parnate and thalidomide were anxiety and depression, or unless Mer/29
created cholesterol which led to a heart attack, great reliance on Cutter
alone may be unwise. The Sabin vaccine, of course, falls in line with
the "opposite-from that intended" argument used in Cutter, but plaintiffs
in other drug cases will have to show that the side effect injury itself was
so serious as to overcome the policy favoring drug firms. Certainly, in
the event that privity is retained in these new drug cases, it should be ex-
tended to the intended users.
UNIFORM COMMERCIAL CODE
Although the UCC was not designed "to disturb those lines of case
law growth '"" which are liberalizing recovery in warranty, there are
some noteworthy modifications. Section 2-313 deals with an express war-
ranty between seller and buyer. Express warranty rests on the "dickered"
aspects of individual bargaining, whereas implied warranty rests on the
surrounding facts and circumstances of the sale."' In some jurisdictions,
the wording of this section may have a liberalizing effect. The words
"any affirmation" are meant to eliminate requirements of intent or re-
liance."'
Merchantability
Section 2-314 deals with the implied warranty of merchantability.
Instead of a requirement that the buyer rely on the seller's skill or judg-
Co., 217 N.Y. 382, 111 N.E. 1050 (1916). That is, the implied warranty extends to users
and others injured by the product.
109. Gottsdanker v. Cutter Labs., 182 Cal. App. 2d 602, 6 Cal. Rep. 320 (1960).
110. UCC 5 2-313, comment 2.
111. UCC § 2-313, comment 1.
112. UCC § 2-313, comment 3.
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ment, this section demands that the seller be a merchant dealing in the
goods sold. In section 2-314, the implied warranty arises in a contract of
sale, course of dealing, or usage of the trade. This section includes the
serving of food or drink. Six requirements113 of merchantability are
outlined in this section. Drugs, for example, which are not compatible
with the purpose for which intended are unmerchantable under this
section.
Fitness
Section 2-315 deals with the implied warranty of fitness for a par-
tcular purpose. There are two requirements: (1) the seller must have
reason to know the particular purpose for which the goods are required;.. 4
and (2) the buyer must prove he relied on the seller's skill and judg-
ment in the matter."' The comments following this section make it
clear that the implication of warranty is a factual as opposed to a legal
question. The buyer must actually rely on the seller, but need not
affirmatively indicate his reliance to the seller so long as the circum-
stances are such that the seller should know of it."6
Class of Plantiffs
Little difficulty is anticipated with sections 2-313, 314, 315, or 316,
simply because they effect little change in existing law On the other
hand, section 2-318 is of particular interest in the new drug cases for
113. UCC § 2-313.
Goods to be merchantable must be at least such as
a) pass without objection in the trade under the contract description; and b) in the
case of fungible goods, are of fair average quality within the description; c) are
fit for the ordinary purpose for which such goods are used; and d) run, within the
variations permitted by the agreement, of even kind, quality and quantity within each
unit and among units involved; and e) are adequately contained, packaged, and
labeled as the agreement may require; and f) conform to the promises or affirma-
tions of fact made on the container or label if any.
114. UCC § 2-315.
115. Ibid.
116. Sections 2-314 and 2-315 define two different kinds of implied warranty. The key to
2-315 is contained in the words "particuJar purpose," and this is said to envisage a specific
use by the buyer which is peculiar to the nature of his business. UCC § 2-315, Comment 2.
Conceivably, a product could be either unmerchantable or not fit for the particular purpose
intended, or both.
It is worth noting that there may be liability under § 2-315 for allergic reactions if the
seller, at the time of the sale, had reason to know of the buyer s peculiar sensitivity and the
buyer relied on the sellers skill to furnish a suitable product. Wright v. Carter Prods.,
Inc., 244 F.2d 53 (2d Cir. 1957).
This section also modified the rule which prevented recovery if the buyer requested a
patent or trade name. Comment 5 following this section in the 1962 revision of the UCC
states that "the mere fact that the article purchased has a particular patent or trade name is
not sufficient to indicate non-reliance by the seller as adequate for the buyer s purpose."
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some jurisdictions. It states:
A seller's warranty whether express or implied extends to any natural
person who is in the family or household of his buyer or who is a guest
m his home if it is reasonable to expect that such person may use,
consume or be affected by the goods and who is injured m person by
breach of the warranty. A seller may not exclude or limit the operation
of this section." 7
While the last sentence does not prevent disclaimers, it does prevent a
seller from limiting the warranty to the immediate buyer. For some
jurisdictions, this secuon may have extended the scope of coverage; for
others, it may have given a rebirth to the concept of privity by describing
the class of plaintiffs and defendants." 8 The comments, however, quick-
ly halt such speculation by saying that the section "is not intended to
enlarge or restrict the developing case law on whether the seller's warran-
ties extend to other persons
Notice of Breach
Section 2-607 deals with nonce of breach. The buyer is required to
notify the seller within a reasonable time after injury that the transaction
may involve a breach.' This does not mean the notice must contain
a dear statement of all objections, a threat of litigation, or a claim for
,damages. Simple notice is required in reasonable time, but more tume
is accorded retail consumers than merchant buyers. 2' If the seller's
breach is made in bad faith the time requirement is given a very liberal
construction. 2
2
STRICT TORT LIABILITY
Several ratonales have been set forth to justify strict tort liability.' 23
Among the most common are: (1) One who undertakes to supply prod-
ucts which may endanger person or property has a special responsibility
imposed upon him to protect those who are forced to rely on his products.
(2) The manufacturer is in the best position to discover defects and
117. UCC § 2-318.
118. Freedman, Products Liability Under UCC in New York and Other States, 19 FOOD,
DRUG CosM. L.J. 178, 182 (1964).
119. UCC § 2-318, comment 3. (Emphasis added.)
120. UCC § 2-607, comment 4, par. 2.
121. UCC § 2-607, comment 4, par. 1.
122. UCC § 2-312, comment 2. The notice requirements, as other sections of the Code,
-will have to be analyzed on a case-by-case approach which is beyond the scope of this artide.
However, it is important to realize the potential variations the UCC may effect in the warranty
law of those states which have adopted the Code.
123. Dickerson, The Basis of Strict Products Liability, 16 FOOD DRUG CosM. LJ. 585, 589
(1961); Green, Should the Manufacturer of General Products be Liable Without Negligence,
24 TENN. L REv. 928 (1957); Pound, Law in the Serice State: Freedom versus Equality,
36 A.B.A.J. 977, 981 (1950).
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should therefore be motivated to Improve his product and use all possible
care. (3) Strict liability generally places the loss on the one best able
to handle and distribute it.
2 4
Although strict liability has been criticized as an expression of radical
jurisprudence, of dubious morality, as well as a novel social theory and
bad economics," 5 it is here to stay In the area of drugs, strict liability
simply means that the manufacturer will be liable without fault for an in-
jury caused by his product. One need only prove that the drug caused
the injury. A proposed addition to the Restatement of Torts'26 adds the
requirement that the product be "defective" or "unreasonably dangerous."
Tins new section"' originally applied only to strict liability for food in-
juries; however, the American Law Institute's recent Tentative Draft No.
10 for the Restatement of Torts, Second, section 402A recognized the
rapid changes in this area and proposed strict liability for any product
which is sold in a dangerous or defective condition. The suggested limi-
tations on the application of this rule have some relevance in the drug
cases. In comment K to section 402A it is noted that certain products
such as drugs and vaccines are often unavoidably unsafe. However, it is
clearly stipulated that the drug product be properly prepared and mar-
keted and proper warnng be given where the situation calls for it, other-
wise the rule of strict liability will apply. Even with this stipulation,
the new Restatement section appears to be perpetuating a distinction based
on the manufacturer's ability to know of the presence of a dangerous de-
fect. If the reasons given in support of strict liability are to retain any
validity, no exception for drugs should be made.'
124. RESTATEMENT (SECOND), TORTS § 402A, comment c (Tent. Draft No. 10, 1964)
125. Coleman, The Deep Pocket Rule and the Jumping Warranty: Strict Products Liability
of Manufacturers, 18 FOOD DRUG COSM. L.J. 654 (1963)
126. RESTATEMENT (SECOND), TORTS, § 402A (Tent. Draft No. 7, 1963).
127 Ibid. The section reads as follows:
SPECIAL LIABILITY OF SELLER OF PRODUCr TO USER OR CONSUMER
(1) One who sells any product in a defective condition unreasonably dangerous
to the user or consumer or to his property, is subject to liability for physical
harm thereby caused to the ultimate user or consumer, or to his property, if
(a) the seller has exercised all possible care in the preparation and sale of his
product, and
(b) the user or consumer has not bought the product from or entered into
any contractual relation with the seller.
Caveat- The Institute expresses no opinion as to whether the rules stated in this
Section may apply
(1) to harm to persons other than users or consumers;
(2) to the seller of a product expected to be processed or otherwise changed be-
fore it reaches the user or consumer; or
(3) to the seller of a component part of a product to be assembled.
128. Certainly, no person should go uncompensated for an injury caused by a drug which
medical science is advanced enough to invent and market, but too careless to evaluate and
investigate properly. The problem is not in knowing too little about a drug, but in taking too
little time to apply what is known.
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Further examination of the strict liability theory reveals that the rule
announced in section 402A pertains only to a manufacturer, dealer, or
seller of a product. In addition, the burden is on the injured plaintiff to
show that the product was defective when it left the seller. This includes
"packaging, necessary sterilization and other precautions" necessary to in-
sure the safety of the product through its normal anticipated use. No
distinction should be made between a product which is inherently danger-
ous and one which is impure or contaminated. The term "defective"
should encompass both types of products.
In addition to the defective quality of the product, it must be "un-
reasonably dangerous" to the user or consumer. Essentially, this means
the product must cause an injury not contemplated by the normal expec-
tations of an average person. If an overdose of a normally safe drug
produces injury, there is no proof that it is unreasonably dangerous. But
if the drug is used as prescribed and produces injury which is not a part
of the community's common knowledge as to its characteristics, then the
injury does qualify under section 402A 29 as defective.
In allergy cases, it should be the seller's duty to warn the purchaser
if the product contains a substance to which a relatively large number of
people may be allergic. It is nearly impossible for the consumer to know
just what drugs may be harmful to him. Using a standard of "reasonable
human skill and foresight," the drug manufacturer must discover and
warn of inherent dangers. 3 '
Strict liability is no longer a "novel social theory" and "bad economics";
it is a movement in law which is directly responsive to social needs. The
drug industry purports to protect the public; in pursuance of that ain, the
law should contribute toward complete protection of the consumer.
GOVERNMENT TORT LIABILITY
Recent discussions have suggested the possibility of government lia-
bility for drug injuries brought under the Federal Tort Claims Act
(FTCA) C. Joseph Steder, general counsel for the Pharmaceutical Man-
ufacturers Association, recently addressed the Federal Bar Association on
this very problem. 3' He theorized that a combination of increased gov-
ernment control and scientific advancements are creating a legal duty on
the part of the government to exercise care in testing and approving new
drugs. The drug law amendments of 1962 increase the government's
power and authority, as well as the responsibility and potential liability
of the government.
129. RESTATEMENT (SECOND), TORTS § 402A, comment i (Tent. Draft No. 10, 1964).
130. RESTATEmE:NT (SEcoND), TORTS § 402A, comment j (Tent. Draft No. 10, 1964).
This same result is reached now in many states by case law.
131. Stetler, Government Tort Liability Under the Drug Amendments of 1962, 3 J. NEw
DRUGS 266 (1963).
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Outside of the FTCA there is little authority for government liability
based upon certification, license, approval, or "guarantee" of a product.'
Under the Federal Tort Claims Act, however, there is some precedent
which may illumine the area of drug liability. The act subjects the gov-
ernment to liability for negligent acts of its employees who are acting
in the scope of their employment. The types of injuries covered include
loss, personal injury, or death. Mr. Stetler points out that government
action under the new drug laws comes within the scope of the act as in-
terpreted. Indeed, because of its benevolent purpose the act has been
liberally construed; but the exceptions within the act are correspondingly
subject to strict construction.'33
The Food, Drug and Cosmetics Act may also provide some remedy
in drug cases. Duty, the basic element in any negligence action, exists
in the act and is said to exist for the ultimate consumer.' However,
the nature of this duty did prevent recovery in one tort claims case based
on the Food, Drug and Cosmetics Act.3"' Anglo-American & Overseas
Corp. v Unted States involved an action by a wholesaler-purchaser of
tomato paste against the federal government. The government elected
to test a sample of the imported food product and subsequently cleared
its shipment. Later, it was discovered that the shipment was impure and
the entire lot was destroyed. The wholesaler based his claim on the de-
fendant's failure to reject the paste as an impure inported product. Neg-
ligence in the original examination and issuance of a certificate clearing
the product was alleged. The court said that the duty under the Food
and Drug Act is primarily for the ultimate consumer3 6 not for an inter-
mediate dealer. This would seem to open a door for drug consumers who
depend on the government to test not just a sample, but, as is the case
with some drugs, every batch, lot, or shipment. However, as quiddy as
this "door" is opened, it is slammed shut. The Overseas Corp. case also
added weight to a defense which has been developing since the early
132. It has been determined that the approval of a structural design by the Civil Aeronautics
Authority is nothing more than a determination of conformity with minimum standards of
the Civil Air Regulations. Prashker v. Beech Aircraft Corp., 258 F.2d 602 (3d Cir.), cert.
denied, 358 U.S. 910 (1958) The court directed a verdict for defendant without considering
the argument that certification was conclusive as to the safety and fitness of the plaintiff's
design. This case was directed against the manufacturer, not the government, so there is no
law clarifying the effect of government approval of aircraft or, similarly, of drugs.
133. Jones v. United States, 126 F. Supp. 10 (D.D.C. 1954), aff'd, 228 F.2d 52 (D.C. Cir.
1955).
134. United States v. Sullivan, 332 U.S. 689 (1948); United States v. Dotterweich, 320 U.S.
277 (1943)
135. Anglo-American & Overseas Corp. v. United States, 144 F. Supp. 635 (S.D.N.Y.
1956), af'd, 242 F.2d 236 (2d Cir. 1957).
136. Id. at 636.
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fifties."" To understand this defense, the FTCA must be examined to
discover its own specific exceptions. One such exception holds the entire
act inapplicable in cases where the claim arises out of misrepresentation
or deceit... The Overseas Corp. case held that the exception encom-
passes misrepresentations which are negligent as well as those which are
wilful." 9 Other cases have held further that even where there is a negli-
gent act, the FTCA will not apply if the act became operative through
misrepresentations. Thus, where a negligent act is coupled with a re-
sultant false misrepresentation on which plaintiff relies to his economic
detriment, the real cause of injury is said to be the misrepresentation. 4 '
In capsule form, it can be said that the trend of recent cases is that
there is no liability for misrepresentation, even if negligently made, so
long as the resulting damage is of an economic or business character.
Were the government to be sued for negligently approving a drug which
caused physical harm, the courts could find liability simply by refusing to
extend the Section- 2680(h) misrepresentation defense against an ulti-
mate consumer with this type of injury. This could be based on the gov-
ernment's extensive duty to refrain from approving .a drug which is un-
safe, impure, or ineffective. It seems, though, that these physical harm
cases could meet difficulty in maintaining the theory that negligence be-
comes operative through misrepresentation. In other words, there are
two approaches. (1) Plaintiff says that he was injured because of de-
fendant's representations as to the safety of the drug. This contemplates
the possibility of the court's disallowing the misrepresentation defense
on the basis of the policy stated above. (2) Plaintiff says he is the ulti-
mate consumer who has suffered bodily injury from defendant's negli-
gent acts, though no misrepresentations may have been made directly to
him. In this case, there may be recovery without any conflict with
2680 (h) '4
137. National Mfg. Co. v. United States, 210 F.2d 263 (8th Cir.), -cer. dented, 347 U.S.
967 (1954).
138. 28 U.S.C. § 2680(h) (1958).
139. Anglo-American & Overseas Corp. v. United States, 144 F. Supp. 635, 637 (S.D.N.Y.
1956):, a 'd, 242 F.2d 236 (2d-Cir. 1957).
140. The line of cases espousing the defense seems t6'have been solidified by the United
States Supreme Court-deasion in United States v. Neustadt, 366 U.S...696, 702 (1961), where
it was -said that the misrepresentation exclusion bars claims arising out of negligence as well
as intentional misrepresentation. But this Tort Claims Act 'case was 'based on the -National
Housing Act where the Federal Housing Administration, insured the partial -repayment cif
certain loans. The alleged negligence was in furnishing a statement reporting.an-inaccurate
FHA inspection and appraisal. The plaintiff purchaser of a home relied on the representa-
non that there were no defects. The plaintiff's damages were a loss in value dueto cracking
in the ceiling of the house - an economic loss. Indeed, all of, the cases which deny recovery
under this section of the FTCA deal with misrepresejitanons which" resulted in a pecuniary
loss. This is the basis for distinguishing this defense from ourpresent'drug fact situations -
personal as opposed to pecuniary loss.
141. Brown v. United States, 193 F. Supp. 692 (N.D. Fla. 1961) .
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Extensive research has uncovered no drug cases which have named the
United States as a defendant; but in light of the increased responsibilities
being assumed by the Food and Drug Administration such a possibility
cannot be foreclosed.
CIVIL LIABILITY
In addition to civil liability of the government itself, it is important
to consider civil liability based on violation of government statute.
Civil liability based on violation of statute is not new; it is a form of
strict liability. Many state pure food acts do in fact make the manufacturer
or seller of defective goods liable to the injured consumer.' If the federal
act contained similar provisions, there would be little need for acrobatics
with warranty concepts, and the field of strict liability would be under
legislative action where many feel it belongs.'
When dealing with a statute which imposes only criminal sanctions,
violation of it can be evidence of negligence,' 44 presumptively negli-
gent conduct, 4 ' or negligence per se. 4 ' It is hornbook law that com-
pliance with a criminal statute is not necessarily evidence of due care,
since statutes usually describe only minimum standards. Thus, negli-
gence can still be shown by proving a failure to exercise some additional
care.
1 47
A notable case in the food and drug law area is Orthopedic Equip-
ment Co. v Eutsler There, a surgical nail was misbranded according to
FDA standards. As a result, plaintiff's leg was injured when the wrong
size hole was drilled to contain the nail. The court said:
[Although] the Federal Food, Drug and Cosmetic Act does not ex-
pressly provide a civil remedy for injured consumers, [it] does
impose an absolute duty on manufacturers not to misbrand their pro-
ducts, and the breach of this duty may give rise to civil liability.
[We] think that a violation of the Federal Food, Drug and Cosmetic
Act is negligence per se in Virginia, and that the District Judge cor-
rectly based his charge on that premise. 49
142. Meshbesher v. Channellene Oil & Mfg. Co., 107 Minn. 104, 119 N.W 428 (1909);
Great Ad. & Pac. Tea Co. v. Hughes, 131 Ohio St. 501, 3 N.E.2d 415 (1936).
143. PROSSER, TORTS § 84 (2d ed. 1955); Patterson, The Apportionment of Basmess Risks
Through Legal Devices, 24 COLUM. L. REv. 335, 358 (1924); Prosser, The Assault Upon
the Citadel (Strict Liability to the Consumer), 69 YALE I.J. 1099, 1134 (1960)
144. Guinan v. Famous Players-Lasky Corp., 267 Mass. 501, 167 N.E. 235 (1929); Jones
v. Co-operative Ass n, 109 Me. 448, 84 Ad. 985 (1912)
145. Satterlee v. Orange Glenn Sch. Dist., 29 Cal. 2d 581, 177 P.2d 279 (1947), rev'd on
other grounds, 50 Cal. 2d 617, 327 P.2d 897 (1958)
146. Martin v. Herzog, 228 N.Y. 164, 126 N.E. 814 (1920)
147 PROSSER, ToRTs § 35, at 205 (3d ed. 1964).
148. 276 F.2d 455 (4th Cir. 1960)
149. Id. at 460-61.
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An expansion of this concept can be expected as one of the first new
results of the pending drug litigation. The Mer/29 cases are in the best
position to take advantage of the Orthopedic case rule, because these cases
involve criminal sanctions imposed for violation of the act. 5 ' Other
cases which do not have a similar advantage must first prove that the drug
manufacturer did violate the act in order- to base any civil liability on a
breach of the statutory duty. This will be difficult, for much of the in-
formation concerning production, testing, safety, and efficacy is kept con-
fidential.
SPECIFIC DEFENSES
Allergy
The allergy problem is an additional aspect of the earlier discussion
of causation. If the defendant-manufacturer knows or has reason to know
of certain allergic risks inherent in a particular drug, there ought to be a.
duty to warn the consumer. 5' Absent such warning, there is negligence.
How specific the warning must be is still an open question.
With respect to allergic risks, there is no analogy to food cases as ex-
ists in the area of warranty-privity. When food is sold in its natural state
and consumption results in an allergic reaction, there is no liability.'52
One might argue that since drugs are like food for purposes of privity,
they are, likewise, like food with respect to recovery for allergic injuries.
However, drugs are not in a natural state like strawberries; they are artifi-
cial products. It is the processing or manufacture of the drug wich ap-
pears to distinguish it legally from unprocessed natural food products.
Hence, liability for an allergic drug injury is not summarily excluded. On
the other hand, one could attack the "natural-processed" distinction by say-
mg that all products, even food, undergo some processing. The seller has
a responsibility to inspect and maintain the qualitf of his product; he is in
a better posiion to discover risk and thus has an obligation not to sell
poisoned strawberries or defective drugs.
It has been noted that the mechanism involved in allergy is similar
to immunization. 5 ' When a foreign substance is introduced into the
body, antibodies are formed to ward off future attacks from the disease.
Allergy is produced in somewhat the same -manner. Antigens (for-
eign substances) intiate a sensitivity reaction which results in an "aller-
gic" disease. Therefore, the plaintiff whose resistance would make him
150. Loory, Hid Drug Danger, Firm Gets Top Fine, N.Y. Herald Tribune,.June.5, 1964,
pp. 1, 14, col. 1.
151. 1 FRUMmR & FRIDMAN, PRODUCTS LIABILrTY § 2504, at 667 (1960).
152. Bennett v. Pilot Prods. Co., 120 Utah 474, 235 P.2d 525 (1951).
153. Horowitz, Allergy of the Plaintiff as a Defense in Actions Based Upon Breach of Im-
plied Warranty of Quality, 24 So. CAL. L REv. 221, 224 (1950).
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susceptible to an infectious disease carried in a product is not in any dif-
ferent legal posture than an individual whose resistance would make him
sensitive to an antigen in a product. 5 ' The legal consequences of the
above comparison are obvious. Although some limitations are offered,
.e., where the vendee had sufficient foreknowledge of the presence of
antigens, this reasoning would eliminate the defense of allergy. Also,
although it might be easier to prove that plaintiff's drug injury is due to
other causes, the defense of unusual susceptibility seems to be available.15"
But with foreknowledge of a susceptibility, the defendant may still be
liable. 5 '
Disclaimer
Section 2-316 of the UCC provides that wherever a disclaimer is rea-
sonable, it will be construed to be consistent with the warranties. To
negate an inplied warranty of merchantability, the negating words must
mention merchantability If the disclaimer is in writing, it must be con-
spicuous to the consumer. All implied warranties may be excluded either
by the expressions "as is," "with all faults," or when the buyer has first
fully examined the goods. A particular course of dealing may indicate
the exclusion of all implied warranties.
Plaintiff may be saved, however, by section 2-302 (1) of the UCC
which permits a court to enforce all portions of a contract except the dis-
claimer, if it is not unconscionable. The court can pass directly on this
matter using a general test of circumstances and trade custom. But since
no cases have been decided under section 2-302, it is difficult to assess its
true value in the drug area. The section alms at preventing oppression
and unfair surprise. The test elaborated in the comments is one which
requires sound proof that the disclaimer is unconscionable in light of all
surrounding circumstances.
FOOD AND DRUG LAWS
On May 28, 1964, the Food and Drug Administration approved new
rules which may prove to solve the drug liability problem at its core. Al-
though drugs which are clearly toxic seldom reach the market, other drugs
in which the risk of harm is statistically small are too often distributed
too soon. Many times, extensive use of the drug is required before de-
fects are discovered. The methods of distributing and reporting on new
154. Id. at 236.
155. Willson v. Faxon, Williams & Faxon, 138 App. Div. 359, 122 N.Y. Supp. 778 (1910),
motton to amend dectston dented, 143 App. Div. 961, 128 N.Y. Supp. 1151 (1911);
Singer v. Oken, 193 Misc. 1058, 87 N.Y.S.2d 686 (N.Y. City Ct. 1949); cf. Machltt v.
Myers, 23 Ohio App. 160, 155 N.B..248 (1926)
156. Gerhin v. Brown & Sehler Co., 177 Mich. 45, 143 N.W 48 (1913).
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drugs lies dose to the heart of this problem. One of the physician's pri-
mary sources of information about a drug is from the drug companies
through their distributors and salesmen - "detail men." The drug com-
panies likewise depend upon the doctors to report on the success of a drug.
The flow of information between the company and the investigators is
not, however, equal in both directions. The doctors are much more quickly
informed of the merits of a drug than are the manufacturers informed of
its defects. Doctors' distaste for paper work and detailed reports also
hinders reporting. The duty, therefore, must be placed logically at its
source - the drug companies. There must be a de-emphasis of "sale"
and a concentration on "safety" and efficacy. The Food and Drug Ad-
ministration is moving in this direction.s' The new rules help to pre-
serve objectivity. and accuracy in drug advertisements by providing for
stricter reporting to the FDA of any
information concermng any unexpected side effect, injury, toxicity, or
sensitivity reaction or any unexpected incidence or severity thereof
associated with clinical uses, studies, investigations or tests, whether or
not determined to be attributable to the drug 158
On any new drug application or drug supplement for human use, the
FDA requires a review of all promotional material currently in use, in-
cluding labeling and advertising. If clinical experience indicates the need
for change in claims for effectiveness or in side effects, warnings, or con-
traindications,15 then new advertising which is consistent with results is
to be submitted. The new rules are revolutionary. Not only is the safety
of the drug under careful scrutiny, but also its effectiveness. These
changes will not only lead to a more informed group of decision makers
and a great deal more paper work for drug companies and their research
staff, but hopefully to an informed and protected public.
CONCLUSION
The changing legal picture appears to envisage an expanding liability,
i.e., more protection for the masses of people who are consuming tons of
drugs. The major hurdles are found in proof of causation and adjust-
ments of legal concepts to the many practical problems of science and
157. Stetler, Government Tort Liability Under the Drug Amendments of 1962, 3 J. NEW
DRUGS 266, 268 (1963) '"The availability of these data may affect drug malpractice cases
in the sense of expecting physicians to be more fully informed on the hazards and benefits
of drugs."
158. Food and Drug Rules, 29 Fed. Reg. 7020 (1964), amending 21 C.F.R. S 130.13(b)
(2) (i) (rev. ed. 1964).
159. 21 C.F.R. § 130.35(b) (6) (rev. ed. 1964) But foremost in potential adverse effects
from the new regulations is the possibility of "documentary congestion." The tendency of
the FDA to require submission of nearly every piece of information about a drug may delay
or foreclose the availability of a valuable new medication. Austern, Drug Regulation and
the Public Health, 39 N.Y.U. L. REV. 771, 782 (1964).
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the drug industry Outworn technicalities such as privity are being dis-
carded in an effort to harmonize freedom in the drug industry with re-
sponsibility to the drug user.
The wide publicity given to both drug cures and drug injuries has
created a demanding public. When consumers are no longer in a posi-
tion to bargain and fully understand what they are getting, the drug in-
dustry must take the responsibility for compensating the injured con-
sumer. The difficulty is in tempering the profit motive with social con-
sciousness. The solutions to these problems are heading toward per-
fection of the drug program and protection of the consuming public.
It is hoped that the law may complement the field of medicine in obtain-
ing these ends.
NORMAN RUBINOFF
